Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

Severe Influenza Clinical Trial

Official title: A Multicenter, Randomized, Open Label, Add-on Study to Assess Efficacy and Safety of Xiyanping Injection in Pediatric Participants With Severe Influenza-Like Symptoms

Status Recruiting

Clinical Trial Summary

This is a multicenter, randomized, open Label, add-on study.

Clinical Trial Description

This is an add-on study of efficacy and safety of intravenous injection of Xiyanping injection in pediatric subjects with severe Influenza-Like Symptoms.

The purpose to determine the efficacy and safety of Oseltamivir Phosphate combined with or without Xiyanping injection in the treatment of severe Influenza-Like Symptoms. The study will enroll 72 Pediatric severe Influenza-Like Symptoms volunteers, who will be randomized into 2 groups (1:1 ratio): volunteers from the first group will receive Oseltamivir Phosphate and Xiyanping injection for severe Influenza; volunteers from the second group will receive Oseltamivir Phosphate for severe Influenza. Xiyanping injection will be administration as intravenous injection of 0.4mL/kg/day once daily for 7-10 days concomitantly with Oseltamivir Phosphate for severe Influenza-Like Symptoms. ;

Related Conditions & MeSH terms

• Influenza, Human
• Severe Influenza

• NCT number: NCT03947411
• Study type: Interventional
• Source: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Contact: Xilian Zhang
• Phone: 022-27432299
• Email: yfyiec@163.com
• Status: Recruiting
• Phase: N/A
• Start date: March 4, 2019
• Completion date: March 31, 2020